Intrauterine Contraceptive Devices and Risk of Pelvic Inflammatory Disease

References

• An extremely low-cost option: IUCD Method Brief No. 3. 2003; Kenya Ministry of Health: Nairobi.
   Google Scholar
• AE Washington, SO Aral, P Wolner-Hanssen. Assessing risk for pelvic inflammatory disease and its sequelae. JAMA. 266: 1991; 2581–2586.
   PubMed Web of Science ®Google Scholar
• DA Grimes. Intrauterine device and upper-genital-tract infection. Lancet. 356(9234): 2000; 1013–1019.
   Web of Science ®Google Scholar
• C Coggins, NL Sloan. Prophylactic antibiotics before insertion of intrauterine devices [Comment]. Lancet. 351(9120): 1998; 1962–1963.
   Web of Science ®Google Scholar
• GA Dallabetta, AC Gerbase, KK Holmes. Problems, solutions, and challenges in syndromic management of sexually transmitted diseases. Sexually Transmitted Infections. 74(Suppl.1): 1998; S1–S11.
   PubMed Web of Science ®Google Scholar
• Increasing Access to the IUD: An Inter-Agency Workshop organized by Family Health International's Research to Practice Initiative in collaboration with USAID's Service Delivery Improvement Division. 2003; FHI: Chapel Hill NC.
   Google Scholar
• Expanding Women's Contraceptive Choices: IUCD Method Brief No. 1. 2003; Kenya Ministry of Health: Nairobi.
   Google Scholar
• Improving Access to Quality Care in Family Planning. Medical Eligibility Criteria for Contraceptive Use. 2nd ed. WHO/RHR/00.02. 2000; World Health Organization: Geneva. At: 〈http://www.who.int/reproductive_health/publications/RHR_002_medical_eligibility_criteria_second_edition〉.
   Google Scholar
• World Contraceptive Use. 2001; UN Population Division, Department of Economic and Social Affairs: New York.
   Google Scholar
• TL Walsh, DA Grimes, R Frezieres. Randomized controlled trial of prophylactic antibiotics before insertion of intrauterine devices. IUD Study Group. Lancet. 351: 1998; 1005–1008.
   PubMed Web of Science ®Google Scholar
• SK Sinei, KF Schulz, PR Lamptey. Preventing IUCD-related pelvic infection: the efficacy of prophylactic doxycycline at insertion. British Journal of Obstetrics & Gynaecology. 97(5): 1990; 412–419.
   Google Scholar
• SK Sinei, CS Morrison, C Sekadde-Kigondu. Complications of use of intrauterine devices among HIV-1-infected women. Lancet. 351: 1998; 1238–1241.
   PubMed Web of Science ®Google Scholar
• OA Ladipo, G Farr, E Otolorin. Prevention of IUD-related pelvic infection: the efficacy of prophylactic doxycycline at IUD insertion. Advances in Contraception. 7(1): 1991; 43–54.
   Google Scholar
• L Weström, D Eschenbach. Pelvic inflammatory disease. KK Holmes, PF Sparling, P-A Mårdh. Sexually Transmitted Diseases. 1999; McGraw-Hill: New York, 783–809.
   Google Scholar
• C AbouZahr, E Åhman, R Guidotti. Puerperal sepsis and other puerperal infections. CJL Murray, AD Lopez. Health Dimensions of Sex and Reproduction. 1998; Harvard School of Public Health: Boston.
   Google Scholar
• R Ferraz do Lago, JA Simoes, L Bahamondes. Follow-up of users of intrauterine devices with and without bacterial vaginosis and other cervicovaginal infections. Contraception. 68: 2003; 105–109.
   Web of Science ®Google Scholar
• JD Shelton. Risk of clinical pelvic inflammatory disease attributable to an intrauterine device. Lancet. 357(9254): 2001; 443.
   PubMed Web of Science ®Google Scholar
• R Lu, N Wang, J Zhao. Investigation of intrauterine microbes after intrauterine operation [in Chinese]. Chung-Hua Fu Chan Ko Tsa Chih (Chinese Journal of Obstetrics & Gynecology). 33(3): 1998; 168–169.
   Google Scholar
• J Paavonen. Pelvic inflammatory disease. From diagnosis to prevention. Dermatologic Clinics. 16(4): 1998; 747–756.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR—Morbidity & Mortality Weekly Report 2002;51(No. RR-6).
   Google Scholar
• IF Gareen, S Greenland, H Morgenstern. Intrauterine devices and pelvic inflammatory disease: meta-analyses of published studies, 1974-1990. Epidemiology. 11(5): 2000; 589–597.
   Web of Science ®Google Scholar
• TM Farley, MJ Rosenberg, PJ Rowe. Intrauterine devices and pelvic inflammatory disease: an international perspective [Comment]. Lancet. 339(8796): 1992; 785–788.
   Web of Science ®Google Scholar
• EA Wright, AO Aisien. Pelvic inflammatory disease and the intrauterine contraceptive device. International Journal of Gynecology & Obstetrics. 28(2): 1989; 133–136.
   Web of Science ®Google Scholar
• MS Cohen, GE Henderson, P Aiello. Successful eradication of sexually transmitted diseases in the People's Republic of China: implications for the 21st century. Journal of Infectious Diseases. 174(Suppl.2): 1996; S223–S229.
   PubMed Web of Science ®Google Scholar
• CS Morrison, C Sekadde-Kigondu, WC Miller. Use of sexually transmitted disease risk assessment algorithms for selection of intrauterine device candidates. Contraception. 59: 1999; 97–106.
   Web of Science ®Google Scholar
• Grimes DA, Schulz KF. Antibiotic prophylaxis for intrauterine contraceptive device insertion. Cochrane Database of Systematic Reviews 2001(1).
   Google Scholar
• World Health Organization. Guidelines for the Management of Sexually Transmitted Infections. WHO/HIV_AIDS/2001.01, WHO/RHR/01.10. 2001; WHO: Geneva.
   Google Scholar
• A Meheus. Women's health: importance of reproductive tract infections, pelvic inflammatory disease and cervical cancer. A Germain, KK Holmes, P Piot. Reproductive Tract Infections: Global Impact and Priorities for Women's Reproductive Health. 1992; Plenum Press: New York.
   Google Scholar
• World Health Organization. Investing in Health Research and Development: Report of the Ad Hoc Committee on Health Research Relating to Future Intervention Options. 1996; WHO: Geneva.
   Google Scholar
• J Villar, G Carroli, AM Gülmezoglu. The gap between evidence and practice in maternal healthcare. International Journal of Gynecology and Obstetrics. 75: 2001; S47–S54.
   Web of Science ®Google Scholar